Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans
Open Access
- 11 September 2012
- journal article
- research article
- Published by MDPI AG in Metabolites
- Vol. 2 (3), 596-613
- https://doi.org/10.3390/metabo2030596
Abstract
STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for the treatment of fragile x syndrome (FXS) and autism spectrum disorders (ASD). New clinical data in this article on the metabolism and pharmacokinetics of the R- and S-enantiomers of baclofen presents scientific evidence for stereoselective metabolism of only S-baclofen to an abundant oxidative deamination metabolite that is sterically resolved as the S-enantiomeric configuration. This metabolite undergoes some further metabolism by glucuronide conjugation. Consequences of this metabolic difference are a lower Cmax and lower early plasma exposure of S-baclofen compared to R-baclofen and marginally lower urinary excretion of S-baclofen after racemic baclofen administration. These differences introduce compound-related exposure variances in humans in which subjects dosed with racemic baclofen are exposed to a prominent metabolite of baclofen whilst subjects dosed with STX209 are not. For potential clinical use, our findings suggest that STX209 has the advantage of being a biologically defined and active enantiomer.Keywords
This publication has 26 references indexed in Scilit:
- Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humansBiochemical Pharmacology, 2012
- Arbaclofen Placarbil, a Novel R-Baclofen Prodrug: Improved Absorption, Distribution, Metabolism, and Elimination Properties Compared with R-BaclofenThe Journal of pharmacology and experimental therapeutics, 2009
- Mammalian cytochromes P450—Importance of tissue specificityBiochimica et Biophysica Acta (BBA) - General Subjects, 2007
- SERTRALINE IS METABOLIZED BY MULTIPLE CYTOCHROME P450 ENZYMES, MONOAMINE OXIDASES, AND GLUCURONYL TRANSFERASES IN HUMAN: AN IN VITRO STUDYDrug Metabolism and Disposition, 2004
- Human Extrahepatic Cytochromes P450: Function in Xenobiotic Metabolism and Tissue-Selective Chemical Toxicity in the Respiratory and Gastrointestinal TractsAnnual Review of Pharmacology and Toxicology, 2003
- Plasma-Pooling Methods To Increase Throughput for in Vivo Pharmacokinetic ScreeningJournal of Pharmaceutical Sciences, 1998
- Trypan Blue Exclusion Test of Cell ViabilityCurrent Protocols in Immunology, 1997
- Localization of monoamine oxidases in human peripheral tissuesLife Sciences, 1996
- Pharmacokinetics of baclofen in spastic patients receiving multiple oral dosesInternational Journal of Clinical Pharmacy, 1990
- Baclofen: stereoselective inhibition of excitant amino acid releaseJournal of Pharmacy and Pharmacology, 1980